China Coronary Vaccine Manufacturer Kangshino announced that the company's inhalation of reorganized crown vaccines for reorganization was proposed by the National Health and Health Commission of China.
According to the announcement issued on the website of the Shanghai Stock Exchange on Sunday (September 4), the vaccine was approved by the China National Drug Administration in March 2021.Diseases caused by disease infection.
The announcement also mentioned that if the subsequent Chinese departments are purchased and used by this inhaling vaccine, it will have a certain positive impact on Kangshino's performance.
According to the Chinese Vaccine Management Law, there are special major public health incidents or other emergencies that seriously threaten public health and health.Suggestions can be used urgently within a certain scope and period after organizing and agreed by the State Council's Drug Supervision and Administration Department.
According to the Zhitong Finance and Economics website, the inhalation vaccine developed by Kangxino is a inhaled genetic engineering vaccine that prevents the disease of the crown disease.Immunity, effectively achieve triple comprehensive protection, without muscle injection in the process.
The report also described that this inhalation of vaccines has unique advantages in terms of safety, effectiveness, painlessness, convenience and accessibility.
